Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug
delivery company with an exciting portfolio of proprietary technologies
and a pipeline of innovative controlled release (CR) products, announced
today the appointment of Vipin K. Garg, Ph.D. to the role of Chief
Executive Officer, effective immediately. Dr. Garg succeeds Neos Interim
Chief Executive Officer, Alan Heller, who will continue serving as
Chairman of the Neos Board of Directors. Dr. Garg will also serve as a
member of the Neos Board of Directors.
Dr. Garg has over twenty-five years of experience within the
biotechnology and pharmaceutical industries in both technical and
management positions. He has a proven track record of building and
managing both private and publicly traded companies. Before joining Neos
Therapeutics, he served as President and Chief Executive Officer of
Tranzyme Pharma (NASDAQ: TZYM), where he led the company’s initial
public offering in 2011 and its merger with Ocera Therapeutics (NASDAQ:
OCRX), Inc. in July, 2013.
Neos Therapeutics’ Chairman, Al Heller, stated, “I am excited to welcome
Vipin to the Neos team. He brings to us a wealth of strategic,
scientific and industry experience. Vipin will work closely with the
organization to obtain FDA approval of our existing pipeline, and expand
the use of our proprietary controlled release technologies to create
additional CR orally disintegrating tablets and CR liquids to bring to
market.”
Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of
Apex Bioscience, Inc. (now Curacyte AG of Munich, Germany), and held
senior management positions at DNX Bio-Therapeutics, Inc. until its
acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals,
Inc. (formerly known as Sepracor Inc., now a subsidiary of Dainippon
Sumitomo Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare
Corporation).
Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University
of Adelaide, Australia, and his M.S. from New Delhi, India in 1978. He
was a member of the U.S. Presidential Mission to India led by President
Bill Clinton in March, 2000. He is a past board member of the North
Carolina Biotechnology Center and currently serves on the Executive
Committee of CED (formerly the Council for Entrepreneurial Development).
He was the recipient of the Ernst & Young Entrepreneur of the Year 2009
Award, Carolinas Region.
"I am delighted to join Neos Therapeutics," said Dr. Garg. "Neos has
developed proprietary controlled release technologies. These
technologies are being utilized to develop a pipeline of novel ADHD
products which will advance significantly in the next 12-18 months.
Building on the approval of a generic of Tussionex®, an extended release
cough cold product developed utilizing the Neos technology and
manufactured exclusively by Neos, the company is well positioned for
growth. I look forward to working with the Neos team to expand the
pipeline to additional opportunities including prescription,
over-the-counter and veterinary products in a wide range of therapeutic
areas. “
About Neos Therapeutics
Neos Therapeutics Inc. is a specialty pharmaceutical company focused on
the development, manufacture and sale of FDA approved drug products that
utilize the company’s proprietary delivery technologies. The Neos drug
products are being developed using the Dynamic Time Release Suspension®
(DTRS®) and Rapidly Disintegrating Ionic Masking™ (RDIM™) technologies
that deliver controlled release (CR) small molecule active
pharmaceutical ingredients (APIs) in either liquid or orally
disintegrating tablet (ODT) dosage forms. By utilizing APIs that are
FDA-approved and known to be safe and effective, Neos can reduce
development and regulatory risk and efficiently advance targeted
proprietary Rx products through the FDA’s New Drug Application (NDA)
approval process. For more information, visit www.neostx.com.
Dynamic Time Release Suspension®and DTRS® are registered
trademarks of Neos Therapeutics, LP, an affiliate of Neos Therapeutics,
Inc., and Rapidly Disintegrating Ionic Masking™ and RDIM™ are trademarks
of Neos Therapeutics, Inc.
This press release contains certain ''forward-looking statements''
that include projections and may also include words such as ''may'',
''will'', ''expects'', ''believes'', ''anticipates'', ''plans'',
''estimates'', ''seeks'', ''could'', ''intends'', and other similar
expressions. These forward-looking statements involve risks,
uncertainties, assumptions and other factors that are difficult to
predict and that could cause actual results to vary materially from what
is expressed in or indicated by the forward-looking statements.
Copyright Business Wire 2013